Prognostic significance of maximum standardized uptake value on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in bone sarcomas.

OBJECTIVES This study aims to evaluate the prognostic significance of maximum standardized uptake value (SUVmax) on 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) for bone sarcoma. PATIENTS AND METHODS We retrospectively evaluated 34 patients (24 males, 10 females; mean age 36.6±24.2 years; range, 5 to 77 years) with pathologically proven bone sarcoma who underwent 18FDG-PET/CT for initial staging between September 2013 and September 2017. SUVmax of primary lesions were measured. Cumulative survival rate was calculated to evaluate the prognostic value of 18FDG-PET/CT findings. Survival duration was defined as the elapsed duration from the date of pre-treatment 18FDG-PET/CT scanning until the date of the final examination before the date of death. RESULTS The cut-off value for SUVmax in the definition of progression was 8. Mean SUVmax of the progressive group was statistically significantly higher than the non-progressive group. Distant metastases were present in 14 (41.1%) cases. Mortality and cumulative survival rates were 14.7% and 79.1±0.08%, respectively. CONCLUSION Semiquantitative estimation of primary tumor metabolic activity in terms of baseline SUVmax using 18FDG-PET/CT can predict the overall survival of patients with bone sarcoma.

[1]  Ya Zhang,et al.  Does intensified chemotherapy increase survival outcomes of osteosarcoma patients? A meta-analysis , 2018, Journal of bone oncology.

[2]  O. Atik Which articles do we prefer to publish? , 2018, Eklem hastaliklari ve cerrahisi = Joint diseases & related surgery.

[3]  N. Daw,et al.  PET/CT of Osteosarcoma and Ewing Sarcoma. , 2017, Seminars in roentgenology.

[4]  L. Doyle,et al.  Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone. , 2016, Surgical oncology clinics of North America.

[5]  I. Lewis,et al.  UK Guidelines for the Management of Bone Sarcomas , 2010, Sarcoma.

[6]  Byung Il Kim,et al.  Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma , 2016, PloS one.

[7]  A. Loft,et al.  Semi-Quantitative Calculations of Primary Tumor Metabolic Activity Using F-18 FDG PET/CT as a Predictor of Survival in 92 Patients With High-Grade Bone or Soft Tissue Sarcoma , 2015, Medicine.

[8]  J. Schmitt,et al.  Burden of soft-tissue and bone sarcoma in routine care: Estimation of incidence, prevalence and survival for health services research. , 2015, Cancer epidemiology.

[9]  C. Freeman,et al.  Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas , 2011, Journal of surgical oncology.

[10]  A. Loft,et al.  The diagnostic and prognostic value of 18F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  S. Schuetze Utility of positron emission tomography in sarcomas , 2006, Current opinion in oncology.

[12]  F. O’Sullivan,et al.  Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis , 2002, European Journal of Nuclear Medicine and Molecular Imaging.